226 related articles for article (PubMed ID: 30694571)
21. Acquired haemophilia A with a recalcitrant high-titre factor VIII inhibitor in the setting of interstitial lung disease.
Sun L; Sykes DB
BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28756381
[TBL] [Abstract][Full Text] [Related]
22. Management of acquired haemophilia A.
Tiede A; Scharf RE; Dobbelstein C; Werwitzke S
Hamostaseologie; 2015; 35(4):311-8. PubMed ID: 25564260
[TBL] [Abstract][Full Text] [Related]
23. Predictive significance of anti-FVIII immunoglobulin patterns on bleeding phenotype and outcomes in acquired hemophilia A: Results from the Quebec Reference Center for Inhibitors.
Bonnefoy A; Merlen C; Dubé E; Claus-Desbonnet H; Rivard GE; St-Louis J
J Thromb Haemost; 2021 Dec; 19(12):2947-2956. PubMed ID: 34455699
[TBL] [Abstract][Full Text] [Related]
24. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
Borhany M; Kumari M; Shamsi T; Naz A; Farzana T
J Coll Physicians Surg Pak; 2012 May; 22(5):289-93. PubMed ID: 22538032
[TBL] [Abstract][Full Text] [Related]
25. [Acquired hemophilia A with reappearance of inhibitor 10 years after the completion of immunosuppressive therapy].
Oshida K; Ito T; Shirayama R; Kusuhara K; Sato T; Sakai M
Rinsho Ketsueki; 2021; 62(3):186-189. PubMed ID: 33828012
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Severe Acquired Haemophilia A with Immunosuppressive Agent: A Case Report of One Patient.
Škunca Ž; Peraica AP
Coll Antropol; 2016 Jun; 40(2):139-43. PubMed ID: 29139630
[TBL] [Abstract][Full Text] [Related]
27. Acquired haemophilia: experiences with a standardized approach.
Grünewald M; Beneke H; Güthner C; Germowitz A; Brommer A; Griesshammer M
Haemophilia; 2001 Mar; 7(2):164-9. PubMed ID: 11260276
[TBL] [Abstract][Full Text] [Related]
28. Relapse of Acquired Hemophilia A after COVID-19 Infection.
Marumo A; Sugihara H; Omori I; Morishita E
J Nippon Med Sch; 2024 Jan; 90(6):474-479. PubMed ID: 36823120
[TBL] [Abstract][Full Text] [Related]
29. Acquired haemophilia in association with organ-specific autoimmune disease.
Meiklejohn DJ; Watson HG
Haemophilia; 2001 Sep; 7(5):523-5. PubMed ID: 11554945
[TBL] [Abstract][Full Text] [Related]
30. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
[TBL] [Abstract][Full Text] [Related]
31. Rituximab for treatment of inhibitors in haemophilia A. A Phase II study.
Leissinger C; Josephson CD; Granger S; Konkle BA; Kruse-Jarres R; Ragni MV; Journeycake JM; Valentino L; Key NS; Gill JC; McCrae KR; Neufeld EJ; Manno C; Raffini L; Saxena K; Torres M; Marder V; Bennett CM; Assmann SF
Thromb Haemost; 2014 Sep; 112(3):445-58. PubMed ID: 24919980
[TBL] [Abstract][Full Text] [Related]
32. Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study.
Zhang XH; Zhu XL; Niu T; Sun J; Liu H; Feng R; Yang LH; Wei Q; Ma QH; Wang QM; Feng FE; Fu HX; Mo XD; Lv M; Huang XJ
Thromb Res; 2015 May; 135(5):835-40. PubMed ID: 25747536
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
Reipert BM; van Helden PM; Schwarz HP; Hausl C
Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
[TBL] [Abstract][Full Text] [Related]
34. Acquired hemophilia: a case report and review of the literature.
Mulliez SM; Vantilborgh A; Devreese KM
Int J Lab Hematol; 2014 Jun; 36(3):398-407. PubMed ID: 24750687
[TBL] [Abstract][Full Text] [Related]
35. Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor.
Croteau SE; Abajas YL; Wolberg AS; Nielsen BI; Marx GR; Baird CW; Neufeld EJ; Monahan PE
Haemophilia; 2017 Mar; 23(2):e93-e98. PubMed ID: 28124406
[TBL] [Abstract][Full Text] [Related]
36. Joint bleeds increase the inhibitor response to human factor VIII in a rat model of severe haemophilia A.
Lövgren KM; Søndergaard H; Skov S; Wiinberg B
Haemophilia; 2016 Sep; 22(5):772-9. PubMed ID: 27439658
[TBL] [Abstract][Full Text] [Related]
37. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
[TBL] [Abstract][Full Text] [Related]
38. Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia.
Tay L; Duncan E; Singhal D; Al-Qunfoidi R; Coghlan D; Jaksic W; Szabo F; McRae S; Lloyd J
Semin Thromb Hemost; 2009 Nov; 35(8):769-77. PubMed ID: 20169513
[TBL] [Abstract][Full Text] [Related]
39. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study.
Türkantoz H; Königs C; Knöbl P; Klamroth R; Holstein K; Huth-Kühne A; Heinz J; Eichler H; Tiede A
J Thromb Haemost; 2020 Jan; 18(1):36-43. PubMed ID: 31448877
[TBL] [Abstract][Full Text] [Related]
40. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
Berntorp E
Haemophilia; 2007 Dec; 13 Suppl 5():69-72. PubMed ID: 18078401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
